Thermo Fisher partners with Singapore’s PRECISE to advance SG100K population proteomics biobank

Reuters04-09 20:00

Thermo Fisher partners with Singapore’s PRECISE to advance SG100K population proteomics biobank

Thermo Fisher entered strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance PRECISE-SG100K, a population-scale biobank study.
Partnership targets population-scale proteomics to support earlier disease detection, prevention, patient stratification.
Thermo Fisher will deploy integrated proteomics workflow using Olink PEA platforms alongside Orbitrap Astral mass spectrometry in PRECISE-SG100K.
Study design runs complementary proteomic technologies in parallel across a large longitudinal cohort to improve reproducibility, support regulatory-grade evidence.
Seer participates as research collaboration partner; Novogene will provide lab services for sample processing, data generation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604090800BIZWIRE_USPR_____20260409_BW180970) on April 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626181010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626181010","market":"us","top_or_hot":-1,"title":"Thermo Fisher partners with Singapore’s PRECISE to advance SG100K population proteomics biobank","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Thermo Fisher partners with Singapore’s PRECISE to advance SG100K population proteomics biobank\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Thermo Fisher entered strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance PRECISE-SG100K, a population-scale biobank study.\n        </li>\n<li>\n          Partnership targets population-scale proteomics to support earlier disease detection, prevention, patient stratification.\n        </li>\n<li>\n          Thermo Fisher will deploy integrated proteomics workflow using Olink PEA platforms alongside Orbitrap Astral mass spectrometry in PRECISE-SG100K.\n        </li>\n<li>\n          Study design runs complementary proteomic technologies in parallel across a large longitudinal cohort to improve reproducibility, support regulatory-grade evidence.\n        </li>\n<li>\n          Seer participates as research collaboration partner; Novogene will provide lab services for sample processing, data generation.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604090800BIZWIRE_USPR_____20260409_BW180970) on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Thermo Fisher partners with Singapore’s PRECISE to advance SG100K population proteomics biobank</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThermo Fisher partners with Singapore’s PRECISE to advance SG100K population proteomics biobank\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-09 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Thermo Fisher partners with Singapore’s PRECISE to advance SG100K population proteomics biobank\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Thermo Fisher entered strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance PRECISE-SG100K, a population-scale biobank study.\n        </li>\n<li>\n          Partnership targets population-scale proteomics to support earlier disease detection, prevention, patient stratification.\n        </li>\n<li>\n          Thermo Fisher will deploy integrated proteomics workflow using Olink PEA platforms alongside Orbitrap Astral mass spectrometry in PRECISE-SG100K.\n        </li>\n<li>\n          Study design runs complementary proteomic technologies in parallel across a large longitudinal cohort to improve reproducibility, support regulatory-grade evidence.\n        </li>\n<li>\n          Seer participates as research collaboration partner; Novogene will provide lab services for sample processing, data generation.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604090800BIZWIRE_USPR_____20260409_BW180970) on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1623119135.USD","symbol_name":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL4dZq0K:1","article_id":"2626181010","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626181010","pubTimestamp":1775736043,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Thermo Fisher entered strategic collaboration with Precision Health Research, Singapore  to advance PRECISE-SG100K, a population-scale biobank study.Partnership targets population-scale proteomics to support earlier disease detection, prevention, patient stratification.Thermo Fisher will deploy integrated proteomics workflow using Olink PEA platforms alongside Orbitrap Astral mass spectrometry in PRECISE-SG100K.Study design runs complementary proteomic technologies in parallel across a large longitudinal cohort to improve reproducibility, support regulatory-grade evidence.Seer participates as research collaboration partner; Novogene will provide lab services for sample processing, data generation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688315":"诺禾致源","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","BK4585":"ETF&股票定投概念","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1923622291.USD":"Natixis Thematics Safety R/A USD","LU1815333072.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"AUP\" (USD) INC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1633808545.USD":"ALLIANZ GLOBAL EQUITY GROWTH \"AT\" (USD) ACC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4548":"巴美列捷福持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0096362180.USD":"CT (LUX) I GLOBAL FOCUS \"DU\" (USD)","TMO":"赛默飞世尔","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC"},"translate_title":"赛默飞世尔与新加坡PRECISE合作推进SG100K群体蛋白质组生物库","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688315":0.9,"TMO":0.9},"content_text":"Thermo Fisher partners with Singapore’s PRECISE to advance SG100K population proteomics biobank\n    \n\n\n          Thermo Fisher entered strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance PRECISE-SG100K, a population-scale biobank study.\n        \n\n          Partnership targets population-scale proteomics to support earlier disease detection, prevention, patient stratification.\n        \n\n          Thermo Fisher will deploy integrated proteomics workflow using Olink PEA platforms alongside Orbitrap Astral mass spectrometry in PRECISE-SG100K.\n        \n\n          Study design runs complementary proteomic technologies in parallel across a large longitudinal cohort to improve reproducibility, support regulatory-grade evidence.\n        \n\n          Seer participates as research collaboration partner; Novogene will provide lab services for sample processing, data generation.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604090800BIZWIRE_USPR_____20260409_BW180970) on April 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626181010","isCrawlerRequest":true}